$1000 a pill hep C drug gets TGA approval

Sofosbuvir, a new antiviral that could potentially offer 90% cure rates for hepatitis C with a one-pill-a-day regimen for 8-12 weeks of treatment has been approved by the TGA.

The drug is a once-daily oral nucleotide analogue polymerase inhibitor that works across all genotypes of hepatitis C and can cure up to 90% of patients with certain genotypes of the virus, according to Gilead, which markets the drug under the brand name Sovaldi.